

## Special Issue

# Recent Scientific Advances in Vaccines for Shigella

### Message from the Guest Editors

Diarrheal disease is a pressing global health issue, especially for children in low- to middle-income countries. Shigella is a leading cause of diarrhea-related mortality in children under 5 and ranks second across all age groups. It's also linked to Traveler's diarrhea and post-infectious conditions like reactive arthritis and irritable bowel syndrome (IBS). Antibiotics are commonly used for shigellosis, but the rise of antimicrobial-resistant (AMR) Shigella strains threatens treatment. The WHO designates Shigella spp. as Priority Pathogens for new therapeutics. A viable solution lies in developing an effective Shigella vaccine. Numerous vaccine candidates, including conjugate, outer membrane vesicles, recombinant subunit, and live attenuated vaccines, are in clinical testing. The preclinical pipeline offers additional candidates like killed whole-cell and multi-pathogen vaccines. This Special Issue welcomes contributions on Shigella vaccine development, encompassing preclinical and clinical insights and assay development for evaluating vaccine efficacy and potential protection indicators.

---

### Guest Editors

Dr. Akamol Suvarnapunya

Dr. Kristen A Clarkson

Dr. Renee Laird

Dr. August Louis Bourgeois

---

### Deadline for manuscript submissions

closed (31 December 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/198784](https://mdpi.com/si/198784)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).